Venus Medtech (Hangzhou) Inc.
Venus Medtech (Hangzhou) Inc. (HKSE: 2500) is trading at HK$1.19, about ₹15 at today's HKD/INR rate, as of 25 Sep 2026, 3:59 AM ET, up 1.71% today. Indian residents can buy Venus Medtech (Hangzhou) from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
HK$1.17
Today's high
HK$1.22
52 week low
HK$0.94
52 week high
HK$3.86
2500 opened at HK$1.17, closed previously at HK$1.17, and has traded between HK$0.94 and HK$3.86 over the past 52 weeks.
About
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-Vitae, a balloon-expandable dry-tissue product; Venus-PowerX, a self-expanding dry-tissue product; Cardiovalve, a transcatheter valve replacement system for the treatment of patients with mitral regurgitation and in pivotal clinical trial for the treatment of patients with tricuspid regurgitation; Liwen RF, a radiofrequency ablation system for the treatment of hypertrophic cardiomyopathy; and renal artery denervation ablation system for the treatment of hypertension. In addition, the company offers procedural accessories comprising catheter sheath product and balloon catheter. Venus Medtech (Hangzhou) Inc. was incorporated in 2009 and is headquartered in Hangzhou, the People’s Republic of China.
Key statistics
Avg. volume
1.11M
Market cap
HK$524.80M
P/E Ratio
-0.96
Price-to-sales ratio
1.76
Enterprise value
CN¥562.84M
Free cash flow yield
-80.17%
Debt-to-equity ratio
0.13
Return on equity
-28.24%
ROIC
-18.41%
Beta
1.16
Dividend yield
0.00%
Last dividend
HK$0.00
Financial overview
Revenue
CN¥306.79M
Earnings per share
-CN¥0.93
Free cash flow
-CN¥332.12M
Net profit margin
-181.92%
Gross margin
53.10%
EBITDA
-CN¥315.42M
Revenue growth
-34.84%
Similar securities
This is not an investment recommendation
How to buy Venus Medtech (Hangzhou) from India
Indian residents can buy Venus Medtech (Hangzhou) shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.
Search for Venus Medtech (Hangzhou) and place an order
Find Venus Medtech (Hangzhou) by name or by its ticker, 2500, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. Venus Medtech (Hangzhou) trades 7:00 am – 1:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Venus Medtech (Hangzhou) position in HKD and INR. Venus Medtech (Hangzhou) pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Venus Medtech (Hangzhou) from India
Trading and taxes when buying Venus Medtech (Hangzhou) from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm HKT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneVenus Medtech (Hangzhou) does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Venus Medtech (Hangzhou) stock?
Yes. Venus Medtech (Hangzhou) (2500) has been listed on the Hong Kong Stock Exchange since 2019, in the Medical - Specialties industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Venus Medtech (Hangzhou) share cost in rupees?
One Venus Medtech (Hangzhou) share is HK$1.19 — about ₹15 at an HKD/INR rate of 12.23 on 25 Sep 2026. Both the Venus Medtech (Hangzhou) price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Venus Medtech (Hangzhou) from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of Venus Medtech (Hangzhou)?
Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
How are gains on Venus Medtech (Hangzhou) shares taxed in India?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Venus Medtech (Hangzhou) price. Paasa issues a capital-gains statement for your return.
Does Venus Medtech (Hangzhou) pay a dividend?
No. Venus Medtech (Hangzhou) does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Venus Medtech (Hangzhou) from India?
The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.
Is Venus Medtech (Hangzhou) a Hong Kong SAR China company, and does that change how it is taxed?
Venus Medtech (Hangzhou) trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. Venus Medtech (Hangzhou) trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare Venus Medtech (Hangzhou) shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Venus Medtech (Hangzhou) holding, its cost and its closing value.
How do I sell Venus Medtech (Hangzhou) and bring the money back to India?
You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.